The portable device uses HeartBeam's patented 3D vectorelectrocardiography (3D VECG) technology to capture signals from three different projections and deliver a synthetic 12-lead ECG.

When Boston Scientific’s coronary DCB gained approval in the United States, it was a moment the country's cardiologists had been looking forward to for years. The cardiologists who researched the device have now detailed their findings, highlighting the "unmet need" this technology is addressing. 

The FDA-approved technology developed by HeartFlow can predict a patient's long-term risk of target vessel failure as well as more invasive treatments performed inside a cath lab. 

The FDA made a special announcement about its decision, describing the news as "a major advance for public health."

“Aspirin is no longer a one-size-fits-all preventive tool for older adults," according to one specialist with Michigan Medicine. 

Using CT to perform coronary artery calcium scoring on symptomatic chest pain patients can deliver significant value, according to a new data published in Radiology. 

The new software was also added to the FDA's Tap Pilot program, an honor reserved for “high-quality, safe, effective and innovative medical devices."

Data from nearly 9.9 million participants were included in the team’s final analysis. The group emphasized the important role governments can play in trying to reverse the world's reliance on these products.